The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Confidence In A Treatment that’s Setting The Standard1-2
Primary results from a Phase III trial of IBRANCE® plus letrozole compared with placebo plus letrozole in post-menopausal women with endocrine receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) locally advanced and metastatic breast cancer.1,2
Study design and patient populations for the phase III PALOMA-2 Trial
Efficacy outcomes including mPFS, tumour response rates and delay to chemotherapy
FACT-B Quality of Life outcomes
IBRANCE® safety and frequently reported adverse events
Dual inhibition with endocrine therapy
Real-world evidence for IBRANCE® (palbociclib) in advanced Breast Cancer
AI : Aromatase Inhibitor, ER+ : Oestrogen Receptor-positive, ET : Endocrine Therapy, HER2- : Human Epidermal growth factor Receptor 2-negative, HR+ : Hormone Receptor-positive, LHRH : Luteinising Hormone-Releasing Hormone, mBC : metastatic Breast Cancer
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results
IBRANCE® safety information and outcomes
Connect virtually with a Pfizer representative to discuss promotional information on a selected range of products.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021